Zivo Bioscience, Inc. (ZIVO): debt financing — Zivo Bioscience raises $250k initial tranche in $2M convertible debt offering

Zivo Bioscience, Inc.

Issued $250k bridge promissory note with 10% annual interest, compounded annually; due after 2 years or upon $5M+ equity financing.
Note converts at lower of issuance price or 80% of qualified financing share price; prepayment allowed at 115% of principal.
Accompanying warrant to purchase 1,793 shares at issuance closing price, 5-year term, immediately exercisable.
Total offering up to $2M; proceeds for general operations; notes unsecured and junior to secured debt.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Zivo Bioscience, Inc. incurred convertible notes of $250,000 with an accredited investor at 10% interest per annum maturing two years after the date of issuance.

Instrument: convertible notes
Principal: $250,000
Counterparty: an accredited investor
Rate: 10% interest per annum
Maturity: two years after the date of issuance
Event: incurrence

Exact text from the filing

On July 8, 2025, Zivo Bioscience, Inc. (the“Company”) issued a Bridge Promissory Note in the principal amount of $250,000 and accompanying warrant to purchase 1,793 shares

View on SEC.gov

305 debt financings filed in the last 30 days. Browse all debt financings →

Zivo Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001654954-25-008035

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.